RXRX

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) | Rumor.io

Recursion Pharmaceuticals

RXRX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#464

Bullish sentiment (50-day avg)89%

Price to earnings ratio-2.57

Market capitalization2B

Earnings per share-1

Dividend yield (TTM)—

Revenue (annual)74.3M

Net income (annual)-644.8M

Social

What share of all stock conversation is about RXRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0.01% 0	0.01% -0.02

Sep 29

A short interest of around 36% of the float exists, with a high days-to-cover ratio of 12.6, indicating a potential for significant price movement if the stock clears recent highs.
Roche's Investor Day highlighted Recursion Pharmaceuticals as a key example of AI-driven discovery, and the company's partnership with Roche may be worth reevaluating.
An AI model suggests that if Roche were to acquire Recursion, a takeover price of $7-$10 per share is possible, with $8-$9 as a reasonable strategic-acquisition scenario.

Generated by AI

Sentiment

Of the messages about RXRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75.56% -22.01	83.49% -4.47	88.73% +3.14	89.11% +0.73
Bearish	24.44% +22.01	16.51% +4.47	11.27% -3.14	10.89% -0.73

Bullish· Sep 22

The stock has broken out of a falling wedge and is above its 200-day moving average, with a potential RSI overbought signal to confirm the trend reversal.
Recursion Pharmaceuticals has a strong fundamental story, with a loaded setup and a large short interest, and is part of a growing biotech sector with AI and drug discovery capabilities.
The stock is in a strong position, with a high short interest of 35% of the float, and is attempting to break out of a multi-month range, with potential upside to $7-9 and a possible squeeze.

Bearish· May 6

Recursion Pharmaceuticals' cash burn is improving, but still significant, with $81.1M used in the latest quarter compared to $132M in the same quarter last year.
The company's pipeline is moving forward, but early data is "good enough to continue" and not necessarily indicative of long-term success.
Recursion Pharmaceuticals' revenue of $6M is considered "HORRIBLE" and a sign of the company's inability to succeed, with insiders selling and institutions dumping shares ahead of what is expected to be a dilutive share offering.

Generated by AI

Topics

Of the messages about RXRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	57.89%	88.64%	31.97%	12.4%
Technical Analysis	42.11%	11.36%	65.49%	30.34%
Macro	0%	0%	2.25%	35.76%
Earnings	0%	0%	0.28%	0.34%
Analysts	0%	0%	0%	21.14%
Controversies	0%	0%	0%	0.02%

Earnings· Aug 5

Recursion Pharmaceuticals reported Q2 revenue of $19.2M, beating estimates by $3.84M and up 33% YoY.
The company's net loss widened to -$171.9M due to a surge in R&D expenses, which increased by 74% YoY to $128.6M.
Recursion ended the quarter with a strong cash position of $533.8M, providing a cash runway into the fourth quarter of 2027.

Analysts· Dec 17

JPMorgan upgrades Recursion Pharmaceuticals (RXRX) to Overweight from Neutral, raising price target to $11, citing strong efficacy of REC-4881 in familial adenomatous polyposis (FAP) and potential peak sales of over $1 billion.
Analyst Priyanka Grover notes REC-617 shows early promise in ovarian cancer, with JPMorgan estimating a 60% probability of success.
JPMorgan initiates coverage on Recursion Pharmaceuticals with a Buy rating and sets a target price of $11, highlighting the company's REC-4881 program as a key driver of growth.

Announcements· Feb 18

Recursion Pharmaceuticals' AI-driven drug discovery platform has been endorsed by NVIDIA, which has held a significant stake in the company for two years.
NVIDIA's exit from Recursion Pharmaceuticals has caused a selloff, reflecting investor concerns over the loss of a high-profile supporter.
Recursion Pharmaceuticals is ahead in experience and AI-native processes, having refined its AI models and built proprietary maps of biology for years, potentially attracting future big pharma partnerships.

Technical Analysis· Jun 10

$RXRX is forming a falling wedge on the weekly chart, with the stock currently above the weekly HMA, and holding this level could lead to a breakout towards $3.5.
The setup is considered solid, with gamma looking favorable for next OPEX, and a potential grind towards $3.5 if the wedge breaks out.
A successful breakout from the falling wedge could lead to interesting gains, with the stock's current position above the weekly HMA and gamma looking solid.

Generated by AI

Community

Of the messages about RXRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60.78%	40.16%	52.06%	38.5%
Newcomers	39.22%	59.84%	47.94%	61.5%

Regulars· Sep 29

The $RXRX short float is around 40%, which could lead to a potential doubling of the stock's value on positive news.
Roche's recent investor day highlighted Recursion Pharmaceuticals as a prime example of AI-driven discovery, which could lead to Roche reevaluating its partnership with Recursion and potentially acquiring the company.
The stock's recent upward momentum and formation of a bull pennant suggest a healthy and strong trend, with some traders believing that a catalyst for further growth is yet to be revealed.

Newcomers· Sep 29

The newcomer's main focus is on the potential for Recursion Pharmaceuticals' AI-driven discovery engine to lead to clinical successes, which could significantly increase the company's value.
The newcomer is closely watching the short interest in RXRX, with ~36% of the float being shorted and a relatively low days-to-cover ratio, which could lead to a potential short squeeze.
The newcomer is also focused on the company's revenue growth and contract stacking, with a notable deal with YeeZo contributing 12% of revenue, and multiple growth channels in place, making it a stock worth watching.

Generated by AI

News

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

5d agoYahoo Finance

Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.05, representing a +2.02% change from its previous close.

7d agoYahoo Finance

Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?

Recursion Pharmaceuticals (RXRX) is back on traders’ screens after a sharp daily move, with the share price closing at US$3.83. Recent returns have been mixed over the past week and month. For context, Recursion Pharmaceuticals has delivered an 8.19% 1-day share price return and a 19.69% 7-day share price return, yet the total shareholder return over the past year is down 22%. This hints at short-term momentum building against a more difficult long-term backdrop and shifting views on the...

11d agoYahoo Finance

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.18, marking a -1.85% move from the previous day.

13d agoYahoo Finance

Recursion Pharma CEO Najat Khan sells $78,822 in stock

19d agoInvesting.com

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

25d agoYahoo Finance

Also Discussed

Investors talking about RXRX also mention

#	Name	Attention
1	EXAI - Exscientia plc	——
2	Absci CorporationABSI	0%+0
3	Prime Medicine, Inc.PRME	0%-0.01
4	Tempus AI Inc Class A Common StockTEM	0%-0.11
5	Beam Therapeutics IncBEAM	0.02%+0.02
6	Intellia Therapeutics, Inc.NTLA	0%+0
7	AbCellera Biologics Inc.ABCL	0.24%-0.06
8	Relay Therapeutics Inc.RLAY	0%new
9	SoundHound AI, Inc. Class A Common StockSOUN	0.02%0
10	Schrödinger, Inc.SDGR	0%-0.01

Recursion Pharmaceuticals, Inc. Class A Common Stock

Healthcare
Biotechnology

Recursion Pharmaceuticals, Inc. Class A Common Stock represents ownership in Recursion Pharmaceuticals, a clinical-stage TechBio company focused on industrializing drug discovery through data-driven biology and chemistry. The company uses automation, artificial intelligence, machine learning, and engineering to map biological systems and identify novel therapeutic candidates. Its work centers on building a technology-enabled platform for discovering and advancing medicines across areas such as oncology, rare disease, and other complex conditions. Recursion also operates in a research and development environment that combines wet-lab biology with computational tools to improve the efficiency of early-stage drug discovery. Headquartered in Salt Lake City, Utah, Recursion Pharmaceuticals plays a specialized role in the biotechnology market as a developer of platform-based drug discovery capabilities and clinical-stage therapeutic programs.

Website

Location

41 South Rio Grande Street

Salt Lake City, UT, 84101

United States

Social

What share of all stock conversation is about RXRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0.01% +0	0.01% 0	0.01% -0.02

Sep 29

A short interest of around 36% of the float exists, with a high days-to-cover ratio of 12.6, indicating a potential for significant price movement if the stock clears recent highs.
Roche's Investor Day highlighted Recursion Pharmaceuticals as a key example of AI-driven discovery, and the company's partnership with Roche may be worth reevaluating.
An AI model suggests that if Roche were to acquire Recursion, a takeover price of $7-$10 per share is possible, with $8-$9 as a reasonable strategic-acquisition scenario.

Generated by AI

Sentiment

Of the messages about RXRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	75.56% -22.01	83.49% -4.47	88.73% +3.14	89.11% +0.73
Bearish	24.44% +22.01	16.51% +4.47	11.27% -3.14	10.89% -0.73

Bullish· Sep 22

The stock has broken out of a falling wedge and is above its 200-day moving average, with a potential RSI overbought signal to confirm the trend reversal.
Recursion Pharmaceuticals has a strong fundamental story, with a loaded setup and a large short interest, and is part of a growing biotech sector with AI and drug discovery capabilities.
The stock is in a strong position, with a high short interest of 35% of the float, and is attempting to break out of a multi-month range, with potential upside to $7-9 and a possible squeeze.

Bearish· May 6

Recursion Pharmaceuticals' cash burn is improving, but still significant, with $81.1M used in the latest quarter compared to $132M in the same quarter last year.
The company's pipeline is moving forward, but early data is "good enough to continue" and not necessarily indicative of long-term success.
Recursion Pharmaceuticals' revenue of $6M is considered "HORRIBLE" and a sign of the company's inability to succeed, with insiders selling and institutions dumping shares ahead of what is expected to be a dilutive share offering.

Generated by AI

Topics

Of the messages about RXRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	57.89%	88.64%	31.97%	12.4%
Technical Analysis	42.11%	11.36%	65.49%	30.34%
Macro	0%	0%	2.25%	35.76%
Earnings	0%	0%	0.28%	0.34%
Analysts	0%	0%	0%	21.14%
Controversies	0%	0%	0%	0.02%

Earnings· Aug 5

Recursion Pharmaceuticals reported Q2 revenue of $19.2M, beating estimates by $3.84M and up 33% YoY.
The company's net loss widened to -$171.9M due to a surge in R&D expenses, which increased by 74% YoY to $128.6M.
Recursion ended the quarter with a strong cash position of $533.8M, providing a cash runway into the fourth quarter of 2027.

Analysts· Dec 17

JPMorgan upgrades Recursion Pharmaceuticals (RXRX) to Overweight from Neutral, raising price target to $11, citing strong efficacy of REC-4881 in familial adenomatous polyposis (FAP) and potential peak sales of over $1 billion.
Analyst Priyanka Grover notes REC-617 shows early promise in ovarian cancer, with JPMorgan estimating a 60% probability of success.
JPMorgan initiates coverage on Recursion Pharmaceuticals with a Buy rating and sets a target price of $11, highlighting the company's REC-4881 program as a key driver of growth.

Announcements· Feb 18

Recursion Pharmaceuticals' AI-driven drug discovery platform has been endorsed by NVIDIA, which has held a significant stake in the company for two years.
NVIDIA's exit from Recursion Pharmaceuticals has caused a selloff, reflecting investor concerns over the loss of a high-profile supporter.
Recursion Pharmaceuticals is ahead in experience and AI-native processes, having refined its AI models and built proprietary maps of biology for years, potentially attracting future big pharma partnerships.

Technical Analysis· Jun 10

$RXRX is forming a falling wedge on the weekly chart, with the stock currently above the weekly HMA, and holding this level could lead to a breakout towards $3.5.
The setup is considered solid, with gamma looking favorable for next OPEX, and a potential grind towards $3.5 if the wedge breaks out.
A successful breakout from the falling wedge could lead to interesting gains, with the stock's current position above the weekly HMA and gamma looking solid.

Generated by AI

Community

Of the messages about RXRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60.78%	40.16%	52.06%	38.5%
Newcomers	39.22%	59.84%	47.94%	61.5%

Regulars· Sep 29

The $RXRX short float is around 40%, which could lead to a potential doubling of the stock's value on positive news.
Roche's recent investor day highlighted Recursion Pharmaceuticals as a prime example of AI-driven discovery, which could lead to Roche reevaluating its partnership with Recursion and potentially acquiring the company.
The stock's recent upward momentum and formation of a bull pennant suggest a healthy and strong trend, with some traders believing that a catalyst for further growth is yet to be revealed.

Newcomers· Sep 29

The newcomer's main focus is on the potential for Recursion Pharmaceuticals' AI-driven discovery engine to lead to clinical successes, which could significantly increase the company's value.
The newcomer is closely watching the short interest in RXRX, with ~36% of the float being shorted and a relatively low days-to-cover ratio, which could lead to a potential short squeeze.
The newcomer is also focused on the company's revenue growth and contract stacking, with a notable deal with YeeZo contributing 12% of revenue, and multiple growth channels in place, making it a stock worth watching.

Generated by AI

Recursion Pharmaceuticals

Social

Sep 29

Bullish· Sep 22

Bearish· May 6

Earnings· Aug 5

Analysts· Dec 17

Announcements· Feb 18

Technical Analysis· Jun 10

Regulars· Sep 29

Newcomers· Sep 29

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know

Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Recursion Pharma CEO Najat Khan sells $78,822 in stock

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Also Discussed

Recursion Pharmaceuticals, Inc. Class A Common Stock

Company Information

Location

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know

Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound?

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Recursion Pharma CEO Najat Khan sells $78,822 in stock

Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?

Also Discussed

Social

Sep 29

Bullish· Sep 22

Bearish· May 6

Earnings· Aug 5

Analysts· Dec 17

Announcements· Feb 18

Technical Analysis· Jun 10

Regulars· Sep 29

Newcomers· Sep 29